Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab 02 February 2023
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Genève og Erlangen – 2. februar 2023: Unilabs, en førende udbyder af diagnostiske services, og Siemens... Read more
Efter et solidt politisk fokus på life science-området, mener Dansk Erhverv ikke, at foden skal slippes... Read more
Biotekselskabet IO Biotech har fået opløftende foreløbige resultater fra et fase 2-forsøg mod lungekræft. Mens... Read more
Et nyt fagligt netværk for kvindelige topledere og specialister med prominente life science-kapaciteter... Read more
Newly appointed CMO with more than 25 years’ experience in vaccine development Fast Track status granted... Read more
Estimated 28% reduction in annual operating expenses for 2023 compared to previously announced guidance... Read more
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more